Patient-identified barriers to immunosuppressive medications are associated with poor adherence and negative clinical outcomes in transplant patients. Assessment of adherence barriers is not part of routine post-transplant care, and studies regarding implementing such a process in a reliable way are lacking. Using the Model for Improvement and PDSA cycles, we implemented a system to identify adherence barriers, including patient-centered design of a barriers assessment tool, identification of eligible patients, clear roles for clinic staff, and creating a culture of non-judgmental discussion around adherence. We performed time-series analysis of our process measure. Secondary analyses examined the endorsement and concordance of adherence barriers between patient-caregiver dyads. After three methods of testing, the most reliable delivery system was an EHR-integrated tablet that alerted staff of patient eligibility for assessment. Barriers were endorsed by 35% of caregivers (n=85) and 43% of patients (n=60). The most frequently patient-endorsed barriers were forgetting, poor taste, and side effects. Caregivers endorsed forgetting and side effects.
can lead to an 8% reduction in graft failure. 5 An important first step to improving adherence behaviors is identifying barriers to adherence encountered by children and young adults who have undergone kidney transplantation. As described in several models (eg, Pediatric
Self-management Model, 6 WHO model of adherence, 7 Health Belief Model 8 ), barriers can be individual, family, healthcare system, or community-level factors that interfere with adherence to the medical regimen. For example, individual barriers may include forgetting to take medications, difficulty swallowing pills, refusal, and side effects, while family barriers include running out of medication, health literacy, and inability to afford the medication. Similarly, barriers in the healthcare system, which are critical for the current study, include poor physician-patient communication around the treatment regimen and prescribed regimens being too complex and difficult to understand. Thus, targeting these barriers is critical for improving adherence behaviors. 9, 10 Research demonstrates that patient-identified adherence barriers are tightly linked with adherence across chronic conditions. 11, 12 In solid organ transplantation, barriers such as being embarrassed to take pills in front of others, feeling like there are too many pills or side effects, and forgetting to take medications are linked to important adverse clinical outcomes, such as rejection, hospitalization, and death. 10 Despite these data, there is little research regarding the implementation of systematic assessment of adherence barriers in clinical practice.
The goal of this project was to standardize adherence barriers assessment using a new barriers checklist based on the larger pediatric adherence literature 9, 11, [13] [14] [15] [16] and integrate screening into clinical practice. Our objective was to develop a process to systematically assess for barriers to taking immunosuppression medications for patients who have undergone kidney transplantation as well as their caregivers as a part of routine clinical care. This included developing a BAT and testing various methods of delivering the tool to patients seen in clinic in a reliable manner. A secondary objective was to report the most frequently reported barriers and whether there was agreement between the patients and their caregivers. We have reported our process according to the SQUIRE 2.0 guidelines. 17 
| METHODS

| Context
| Interventions
| Key drivers
A multidisciplinary team consisting of a patient, nephrology fellow, quality improvement consultants, advanced practice nurse, nurse transplant coordinators, social worker, pharmacist, clinic nurse, adherence psychologists, data analyst, and nephrologist was formed with the goal to create, test, and implement a system to assess and improve medication adherence for solid organ transplant recipients. The team met for 60 minutes each week for planning and development of the system. A necessary early step was to identify the essential factors F I G U R E 1 Key driver diagram for reliable assessment of barriers to adherence or "key drivers" (Figure 1 ) required to reliably identify eligible kidney transplant recipients and screen them for barriers to taking their immunosuppression medications during their clinic visit. The key drivers are the theoretical model for change that are then tested with PDSA cycles, as described by the Model for Improvement, 18 and were developed by group consensus in the first two weekly meetings.
Consensus was determined when all team members were in agreement. PDSA cycles testing interventions that addressed our key drivers were tracked using statistical process control charts. 19 We utilized "Pareto" charts, 20 which are used to identify the most common failure modes to focus interventions where they are most needed, and developed interventions to address these failure modes.
Patient-centered design of the BAT
We created an empirically based questionnaire to screen patients and their caregivers for barriers to taking immunosuppression medications.
The design of the BAT was based on prior work in other pediatric subspecialties, including items on 5-point Likert scales that are used for research purposes. 9, 11, [13] [14] [15] [16] As these tools are too lengthy for clinical practice, a new tool was developed that could be quickly and easily administered and scored in a clinical setting. The BAT contains 14 commonly endorsed barriers with a checkbox next to each item. The types of barriers include logistical issues (eg, forgetting, inconvenience), ingestion difficulties (eg, swallowing, taste), efficacy (eg, feel I don't need it), financial difficulties, regimen characteristics (eg, too many medications, side effects), and patient-specific issues (eg, refusal by child, embarrassment). We modified the BAT using an iterative process incorporating feedback from patients and their caregivers, healthcare providers, and patient education specialists. Specific feedback received from patients included simplifying the wording, using a checklist format, and removing double meaning items. The BAT was used as selfreport tool. While we did not test it in interview format, it could be used in that manner as determined for specific patient needs (eg, poor vision, or for patients that cannot read). The BAT may be obtained from the corresponding senior author upon request to interested individuals.
Identification of eligible patients
We addressed our first key driver to reliably identify patients eligible for barriers assessment. We initially targeted children 10 years of age and older who were one year post-transplant because this population of patients are most likely to encounter adherence barriers. 9, 21 Upon review of the first five patients' completion of the BAT, our group recognized the importance of obtaining patient and caregiver perspectives to adherence barriers, regardless of patient age and time since transplant; therefore, we decided to expand the assessment to all children (and/or their caregivers) who had received a transplant to proactively identify barriers regardless of risk factors. Because caregivers and patients have unique perspectives regarding adherence barriers, 11 we administered a BAT to all patients 10 years of age or older and to all caregivers (regardless of patient age) if they were present. The BAT was administered every 3-6 months. Initially, patients were identified during weekly previsit planning (ie, multidisciplinary team meeting to discuss the laboratory, psychosocial, and medical needs of patients scheduled the following week). Each patient has their own visit planning sheet to facilitate in-clinic care, which we modified to indicate when the patient had most recently completed a BAT and whether they were due for a BAT at their upcoming visit. With future tests of change, we automated the process of patient identification and BAT administration through the EHR using tablets programmed to elicit barriers according to our protocol.
Developing a reliable process to administer the BAT to patients and deliver results to the provider in a manner that supported intervention was the most challenging step. We used successive PDSA cycles to develop such a process. The first trial relied on registration staff to provide the BAT to patients and/or their caregiver at check-in based on a list created during previsit planning. The medical assistant or nurse collected the tool at intake and gave it to the nephrologist for review. The second trial was for the medical assistant or nurse to provide the BAT to the patient and/or caregiver while in the room with the patient, then to give the completed BAT to the nephrologist for review.
Our final system relies on the EHR to automatically alert registration staff at check-in to provide eligible patients with the BAT via tablet.
Results are automatically transmitted from the tablet into a flowsheet within the EHR for review by the nephrologist.
Clearly defining roles for clinic staff
The clinic staff (ie, medical assistants, nurses) are instrumental for interventions to be successful. We held multiple educational ses- 
| Study of interventions
We chose the Model for Improvement 18 as the evidence-based framework to guide implementation of our interventions and statistical process control as our method to evaluate the implementation process. 19 While many frameworks exist for quality improvement and implementation research, we chose these two methods because of their simplicity, our familiarity and experience with their use, 22 and their widespread use in healthcare settings. 23 
| Measures
| Process measure
Our primary measure was the percentage of patients seen in clinic each week who were due for BAT screening (denominator) and who had completed it successfully (numerator). Success was determined if the BAT was provided to eligible patients and returned to the project coordinator. Failures included when: (i) a patient who was due for BAT screening according to our protocol did not receive it, (ii) the patient/caregiver refused to complete the BAT, or (iii) the BAT was not returned to the project coordinator or entered into the system.
We reviewed all failures in a twice-monthly meeting with clinic staff to identify areas of improvement.
| BAT content
We assessed responses to determine the percentage of patients/caregivers that reported at least one adherence barrier and to describe the most frequently reported barriers.
| Statistical analyses
We performed a time-series analysis using statistical process con- We calculated a centerline (median) and 3-sigma (±3 standard deviation) control limits from data in the baseline period and carried them forward for comparison with the post-tablet implementation phase.
Three-sigma control limits are the industry and historical standard used with statistical process control charts and have proven in practice to distinguish between common and special cause variation. 24 We identified data points outside the control limits 19 or consistent with other run chart rules 25 as "special cause" variation indicating improvement to the system, and adjusted the centerline and control limits accordingly. We generated charts in Excel (Microsoft, Redmond, WA, USA 
| RESULTS
| Delivery of BAT
The success of each PDSA cycle was documented on a statistical process control chart (Figure 2 ). Of the three trials performed, the first method (ie, registration providing the BAT to patient/caregiver) was the least reliable. Identified challenges included the following: The third trial (ie, automation of the BAT by triggering an alert at check-in) has been the most successful with 79% of eligible patients completing the BAT. After initial tablet system rollout, we performed iterative PDSA cycles to ensure "firing rules" for the BAT appropriately identified eligible patients. One of our clinic nurses was designated as a "champion" for the barriers assessment project. Empowered to improve assessment reliability, she created a checklist to double-check that eligible patients had received the BAT on the tablet. Ongoing failures that prevent our process from reaching 100% reliability include occasional technical issues with the tablet not firing appropriately and patient refusal. For each trial, completing the BAT required <60 seconds.
| Type and number of barriers endorsed
Barriers assessments were completed by 97 unique transplant patients and/or their caregivers (85 caregivers, 60 patients) representing 92% of our current population of 106 patients ( Table 1 ).
All patients at the time of this project were on twice-daily medication for their primary immunosuppressant (cyclosporine, tacrolimus, and/or sirolimus). For the purposes of this report, only the initial BAT responses are reported if patients completed the BAT more than once over the course of the study. Thirty-five percent of caregivers and 43% of patients endorsed at least one barrier. The most frequently endorsed barriers by caregivers included forgetting, side effects, poor taste, swallowing difficulties, running out of medicine, and child refusal while the most common barriers reported by patients were forgetting, side effects, and poor taste ( Table 2 ). The average concordance between caregivers and patients report of each barrier (n=48) was 0.299.
| DISCUSSION
Using the Model for Improvement 18 and iterative PDSA cycles as well as other quality improvement methods, we implemented a systematic, efficient, and reliable process to assess adherence barriers in a large pediatric kidney transplant practice. After piloting via paper and pencil, we found the most reliable way to ensure eligible patients com- We found that caregivers most commonly endorsed forgetting, side effects, poor taste, swallowing difficulties, running out of medicine, and patient refusal while patients endorsed the barriers of forgetting, poor taste, and side effects. As patients transition from childhood to adolescence, the medical regimen ideally becomes a shared responsibility between the patient and caregiver. While external barriers are more easily detected by a caregiver (eg, difficulty swallowing pills), internal factors (eg, embarrassment) can be more challenging to identify. For example, one patient-parent dyad exemplified these differences with the parent endorsing "refuses to take her medication," as the adherence barrier while the patient endorsed "hates the taste, it's hard to swallow pills, and she does not want others to know she takes medicine" as a barrier. Unknown to the caregiver, these barriers were perceived as defiance or refusal, but obtaining the patient's perspective certainly informs the types of adherence promotion strategies we would offer to this family. It is also important to note that as patients grow older, they can experience shifts in their medication-taking behavior, suggesting a need for reassessment of barriers over time. forgetting was most commonly endorsed by patients and caregivers and fortunately is amenable to intervention. 32, 33 Translating the routine assessment of barriers from research to clinical practice is novel and a necessary first step in developing adherence interventions in the clinical setting. A recent meta-analysis has demonstrated that provider-led adherence promotion efforts are more effective than other evidence-based adherence interventions. 34 Nonetheless, our approach does not address all potential barriers to adherence. For instance, our approach relies on patient/caregiver selfawareness and a willingness to report barriers. It is likely that not all caregivers/patients are consciously aware of their barriers or willing to report them. We believe that creating a culture where discussion of adherence barriers is a routine part of care, normalizes the behavior, T A B L E 2 Barriers to adherence reported by patients and caregivers and will encourage greater willingness to discuss barriers. As an important next step, our team will track patients/caregivers that identify barriers to adherence to investigate whether or not these barriers are associated with clinical outcomes. Additionally, our team has developed patient-centered shared decision-making tools to address specific adherence barriers in clinic, with the goal of improving adherence behaviors and ultimately health outcomes (eg, rejection).
While this is one of the first known clinical implementation studies of routine adherence barriers assessment, it is not without limitations.
First, to most effectively demonstrate improvement in our process, we would have ideally collected several more data points in the "baseline assessment period." However, rather than continuing with a system we knew was unreliable for the sole purpose of further data collection, we applied our learnings to the design of more reliable interventions (EHR-integrated tablets). Second, patients/caregivers were allowed to refuse the BAT and we did not capture reasons for refusal to help us understand this challenge. Anecdotally, some caregivers reported they were uncomfortable using the tablet, which suggests the need for other more preferred methods of completion, such as paper-pencil
versions. An important next step in this project is to collect data regarding why certain patients and/or caregivers refuse to complete the BAT. Finally, our barriers data may be biased toward those willing to participate. Nonetheless, we currently have less than 20% refusal at any given visit and more than 90% of our caregivers/patients have completed at least one barriers assessment. Despite these limitations, we believe the principles and approach outlined herein can be applied to many chronic conditions.
In conclusion, we developed and implemented a reliable clinic- 
AUTHORS' CONTRIBUTIONS
Varnell: Contributed to the design of the study, design of the data collection, acquisition of the data, drafted the initial manuscript, revised the manuscript, and contributed to the analyses; Loiselle: Contributed to the design of the study, design of the data collection, drafted portions of the initial manuscript, revised the manuscript, and contributed to the analyses; Nichols: Contributed to the design of the study, acquisition of the data, and critically reviewed the manuscript; Dahale:
Contributed to the design of the study, design of the data collection, and critically reviewed the manuscript; Goebel: Contributed to the conception and design of the study and critically reviewed the manuscript;
Pai: Contributed to the design of the study, design of the data collection, critical review and revision of the manuscript, and contributed to the analyses; Hooper: Contributed to the conception and design of the study, design of the data collection, critical review and revision of the manuscript, and contributed to the analyses; Modi: Contributed to the conception and design of the study, design of the data collection, critical review and revision of the manuscript, and contributed to the analyses; All authors: Approved the final manuscript as submitted.
